LRRC74B: A promising drug target and biomarker for cancer (G400891)

Target Name: LRRC74B

NCBI ID: G400891

LRRC74B

Other Name(s): leucine-rich repeat-containing protein LOC400891 | LRRC74B variant 2 | Leucine rich repeat containing 74B, transcript variant 2 | leucine rich repeat containing 74B

LRRC74B: A promising drug target and biomarker for cancer

Introduction

The search for new cancer treatments and biomarkers has led to the identification of a promising protein: LRRC74B (Leucine-rich repeat-containing protein LOC400891). This protein has been shown to play a critical role in various cellular processes, including cell signaling, DNA replication, and stress responses. Therefore, it is a potential drug target and biomarker for cancer.

The structure and function of LRRC74B

LRRC74B is a protein that contains a unique repeating unit. This unit is made up of four different amino acids: lysine, histidine, isoleucine and phenylalanine. This repeating unit is the signature feature of LRRC74B and is an important marker that distinguishes it from other proteins.

The function of LRRC74B is closely related to many biological processes. For example, it is a cell cyclin involved in the S phase of the cell cycle. In S phase, LRRC74B binds to histones and helps histones perform DNA replication in S phase. In addition, LRRC74B is also closely related to the DNA damage repair pathway and therefore can be used as a potential drug target for DNA damage repair.

LRRC74B is also closely related to cell signaling. For example, LRRC74B can bind to FAK (Focal Adhesion kinase) to promote the interaction between cells and the extracellular matrix, thus participating in cell adhesion and migration. Therefore, LRRC74B can be used as a target for the treatment of cancer, especially the treatment of tumor cell metastasis.

The biological functions of LRRC74B make it an ideal drug candidate as a cancer treatment target. For example, compounds related to LRRC74B have been developed as drugs to treat a variety of cancers, including breast, lung, and prostate cancer. These compounds inhibit the function of LRRC74B, thereby inhibiting the growth and spread of cancer cells.

LRRC74B can also be used as a cancer biomarker. Since LRRC74B is expressed in a variety of cancers, it can be used as a biomarker to evaluate tumor growth and progression. In addition, the expression level of LRRC74B can also be used as an indicator to evaluate the prognosis of cancer patients.

Therapeutic prospects of LRRC74B

LRRC74B, as a drug target, has great therapeutic potential. Since LRRC74B is expressed in a variety of cancers, it can be used as a universal drug to treat multiple cancers. For example, LRRC74B can inhibit the function of LRRC74B, thereby inhibiting the growth and spread of cancer cells and providing new treatment options for cancer patients.

LRRC74B can also serve as a specific cancer treatment target. For example, LRRC74B can inhibit the binding of LRRC74B to histones, thereby inhibiting

Protein Name: Leucine Rich Repeat Containing 74B

The "LRRC74B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC74B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets